Background
Breast cancer (BRCA) constitutes one of the principal causes of death among women. The
Conclusions
Elevated GCNT3 expression in BRCA tissues suggests the potential of GCNT3 to be a biomarker for predicting BRCA prognosis. The regulation of p-PI3K and p-AKT levels by GCNT3 appears to considerably inhibit BRCA cell development and progression.
Methods
Analysis involved data sourced from the The Cancer Genome Atlas database (TCGA). Expression levels of GCNT3 were measured using Western blot analysis and immunohistochemistry (IHC). Additionally, cell functionality tests were performed posttransfection with GCNT3-specific interference plasmids to assess the influence of GCNT3 in BRCA by using EdU assay, transwell assay, and flow cytometric assay, as well as PI3K/AKT signaling pathway.
Results
GCNT3 levels were notably elevated in BRCA tissues compared to adjacent noncancerous tissues. Reducing GCNT3 expression significantly diminished the proliferation, invasion, and migration capabilities of BRCA cells (P<0.05) and concurrently increased apoptosis (P<0.05). The data also indicated that GCNT3 may be involved in activating the PI3K/AKT signaling pathway. Conclusions: Elevated GCNT3 expression in BRCA tissues suggests the potential of GCNT3 to be a biomarker for predicting BRCA prognosis. The regulation of p-PI3K and p-AKT levels by GCNT3 appears to considerably inhibit BRCA cell development and progression.